Tomasz Skórski

The paper identifies a DNA-histone methylation axis that drives KMT2A amplifications and rearrangements in leukemia, revealing therapeutic targets.

This study identifies ZNF251 deficiency as a driver of PARP inhibitor resistance in BRCA1-mutant breast cancer, showing that targeting pseudo-senescence with senomorphic or senolytic therapies can overcome resistance.

This study identifies Polθ as a therapeutic target in DNMT3A-mutated leukemia by showing its essential role in DNA repair and replication fork restart, and demonstrates that its inhibition enhances standard therapies.

This study identifies BRG1 as a critical target in Ph-like B-ALL, showing its inhibition leads to cell cycle arrest and improved survival in preclinical models.